Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan.

被引：0
|
作者：
Smith, SM
Johnson, JL
Niedzwiecki, D
Eder, JP
Canellos, GP
Cheson, BD
Bartlett, NL
机构：
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Duke Univ, Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[5] Washington Univ, St Louis, MO USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2500.2500
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2500
引用
收藏
页码：685A / 686A
页数：2
相关论文
共 50 条
  • [31] Topotecan and cladribine with filgrastim support in relapsed, refractory and poor prognosis leukemias: A phase I-II study
    Silverman, LR
    Isola, L
    Brenner, R
    Gabrilove, J
    Mandeli, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 613S - 613S
  • [32] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    BLOOD, 1998, 92 (10) : 235A - 235A
  • [33] A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma
    Mok, TSK
    Wong, H
    Zee, B
    Yu, KH
    Leung, TWT
    Lee, TW
    Yim, A
    Chan, ATC
    Yeo, W
    Chak, K
    Johnson, P
    CANCER, 2002, 95 (07) : 1511 - 1519
  • [34] Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: A phase I/II study
    Bowman, A
    Rye, T
    Ross, G
    Wheatley, A
    Smyth, JF
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3255 - 3259
  • [35] Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
    Twelves, CJ
    Gardner, C
    Flavin, A
    Sludden, J
    Dennis, I
    de Bono, J
    Beale, P
    Vasey, P
    Hutchison, C
    Macham, MA
    Rodriguez, A
    Judson, I
    Bleehen, NM
    BRITISH JOURNAL OF CANCER, 1999, 80 (11) : 1786 - 1791
  • [36] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David J.
    Byrne, Ben
    Qayum, Naseer
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [37] Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study
    van Gijn, R
    Huinink, WWT
    Rodenhuis, S
    Vermorken, JB
    van Tellingen, O
    Rosing, H
    van Warmerdam, LJC
    Beijnen, JH
    ANTI-CANCER DRUGS, 1999, 10 (01) : 17 - 23
  • [38] Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
    C J Twelves
    C Gardner
    A Flavin
    J Sludden
    I Dennis
    J de Bono
    P Beale
    P Vasey
    C Hutchison
    M A Macham
    A Rodriguez
    I Judson
    N M Bleehen
    British Journal of Cancer, 1999, 80 : 1786 - 1791
  • [39] Phase II study of sequential topoisomerase (Topo) targeting regimens (Reg) with irinotecan/oxaliplatin (I/O) followed by etoposide/carboplatin (E/Crb) in chemonaive patients with extensive small cell lung cancer (SCLC)
    Rossman, Joanne F.
    Reddy, Vishnu
    Oster, Robert
    Prescott, Betty
    Messer, Anna
    Robert, Francisco
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S468 - S468
  • [40] Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Bitran, J. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 243 - 243
12345